Free Trial
NASDAQ:ABSI

Absci Q2 2023 Earnings Report

Absci logo
$3.03 0.00 (0.00%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.04 +0.01 (+0.30%)
As of 05/2/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Absci EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
$3.37 million
Expected Revenue
$2.59 million
Beat/Miss
Beat by +$780.00 thousand
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Absci's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Absci Earnings Headlines

KeyBanc Reaffirms Their Buy Rating on AbSci (ABSI)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Absci price target raised to $9 from $5 at KeyBanc
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

View Absci Profile

More Earnings Resources from MarketBeat